PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22607938-12	2012	Several other cytokines and inflammation markers in tears, including MMP-9, IL-15, IL-17A, and IL-12p70, were markedly reduced in the tofacitinib 0.005% QD group but not the vehicle group.	tofacitinib	134-145	interleukin 15	Homo sapiens	76-81	
23904478-6	2013	Furthermore, the diabetes could be reversed by administration of the Janus kinase 2/3 inhibitor tofacitinib, which blocks IL-15 signaling.	tofacitinib	96-107	interleukin 15	Homo sapiens	122-127	
22960764-3	2012	METHODS: After whole-blood activation with the gamma(c) cytokines IL-2, IL-7, and IL-15, STAT5 phosphorylation was determined in T cells of de novo kidney transplantation patients treated with tofacitinib/basiliximab (n=5), calcineurin inhibitor (CNI) (cyclosporine A)/basiliximab (n=4) or CNI (tacrolimus)-based immunosuppression (n=6).	tofacitinib	193-204	interleukin 15	Homo sapiens	82-87	
22960764-6	2012	In kidney transplantation patients, 7 days after starting tofacitinib/basiliximab treatment, cytokine-induced P-STAT5 was inhibited in CD4(+) T cells (92% for IL-2 activation, 60% for IL-7, and 75% for IL-15), which persisted for the 2-month study period.	tofacitinib	58-69	interleukin 15	Homo sapiens	202-207	
33317858-8	2021	Treatment of 5 patients with recalcitrant GA with tofacitinib inhibited IFN-gamma and oncostatin M, as well as IL-15 and IL-21, activity and resulted in clinical and histologic disease remission in 3 patients and marked improvement in the other 2.	tofacitinib	50-61	interleukin 15	Homo sapiens	111-116	
21106989-3	2011	We evaluated the action of the Jak3 inhibitor CP-690,550 on cytokine dependent ex vivo proliferation that is characteristic of peripheral blood mononuclear cells (PBMCs) from select patients with smoldering or chronic subtypes of ATL, or from those with HAM/TSP whose PBMCs are associated with autocrine/paracrine pathways that involve the production of IL-2, IL-9, IL-15, and their receptors.	tofacitinib	46-52	interleukin 15	Homo sapiens	366-371	
34757416-12	2021	In 1 patient with a robust improvement following treatment with tofacitinib, RNA sequencing identified interferon gamma (IFN-gamma) and interleukin 15 (IL-15) as cytokines with activity both highly upregulated at baseline in lesional skin and subsequently suppressed following tofacitinib treatment.	tofacitinib	64-75	interleukin 15	Homo sapiens	136-150	
34757416-12	2021	In 1 patient with a robust improvement following treatment with tofacitinib, RNA sequencing identified interferon gamma (IFN-gamma) and interleukin 15 (IL-15) as cytokines with activity both highly upregulated at baseline in lesional skin and subsequently suppressed following tofacitinib treatment.	tofacitinib	64-75	interleukin 15	Homo sapiens	152-157	
32738245-5	2021	Here we tested whether tofacitinib, which inhibits IL-15 signaling by blocking janus kinase (jak) 3, might decrease CD8 dependent pathology.	tofacitinib	23-34	interleukin 15	Homo sapiens	51-56	
31375130-6	2019	For example, tofacitinib and upadacitinib were the most potent inhibitors of the JAK1/3-dependent cytokines tested (interleukin [IL]-2, IL-4, IL-15, and IL-21) with lower IC50 values and increased time above IC50 translating to a greater overall inhibition of STAT signaling during the dosing interval.	tofacitinib	13-24	interleukin 15	Homo sapiens	142-147	
32647892-12	2021	Notably, we demonstrate that CD28null T cell expansion was significantly inhibited by Tofacitinib, a selective JAK1/JAK3 inhibitor that blocks IL-7/IL-15 signalling.	tofacitinib	86-97	interleukin 15	Homo sapiens	148-153	
32647892-17	2021	We demonstrate that CD28null T cell expansion is inhibited by Tofacitinib that specifically blocks IL-7/IL-15 signalling.	tofacitinib	62-73	interleukin 15	Homo sapiens	104-109	
25738293-7	2015	Furthermore it was showed that some drugs like tofacitinib or ruxolitinib may influence CD by blocking IL-15 signaling and CD8+ T cell activity.	tofacitinib	47-58	interleukin 15	Homo sapiens	103-108